GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - DISC MEDICINE INC

Financial Performance:

• The company reported over $1.1 billion in pro forma capital, combining existing cash on hand with proceeds from recent financing, providing sufficient runway for commercial launch and Phase 3 progression.
• No specific revenue, earnings, or margin metrics were disclosed as the company remains in clinical development, with commercial revenue expected to commence approximately 16 months post-call.

Guidance and Future Outlook:

• Commercial Launch: Expectation to launch the lead asset (for erythropoietic protoporphyria) within 12-16 months, transitioning the company into a commercial entity.
• Pipeline Milestones: Aiming to transition two other Phase 2 assets (myelofibrosis and polycythemia vera) into pivotal Phase 3 trials by the end of the current year/early next year.
• Regulatory Path: Conducting an End-of-Phase 2 meeting with the FDA to define the Phase 3 design for myelofibrosis, with detailed trial designs to be presented at the ASH conference.
• Long-term Goal: Establish dominance in rare disease anemias with a self-administered, high-efficacy portfolio.

Business Segments and Product Lines:

• Erythropoietic Protoporphyria (EPP): Lead program completed Phase 3 (Apollo study) with successful primary and secondary endpoints; first therapy to target the underlying toxic metabolite accumulation. Market size estimated at 14,000 diagnosed patients (6,000 engaged, 8,000 disengaged).
• Myelofibrosis-Associated Anemia (MF): Phase 2 data shows 70-80% clinical response rates (50% by stringent regulatory calculation); no approved therapies currently exist for this indication. Targeting a comprehensive pivotal trial to include both transfusion-dependent and non-transfusion-dependent patients.
• Polycythemia Vera (PV): In late-stage development with an antibody targeting hepcidin; aims to replace phlebotomy by restricting iron availability while avoiding nutritional deficiency side effects. Targeting 70-80% phlebotomy-free status with a monthly dosing schedule via auto-injector.
• Emerging Indications: Pilot trials initiated for Anemia of Inflammation/Inflammatory Bowel Disease (IBD) and potential extension to Sickle Cell Disease.

Market and Competitive Landscape:

• EPP: Positioned as the first mechanism-based therapy for a disease with limited options; competitors are minimal, with one existing product priced at ~$300k/year (tanning therapy) and another hepatic porphyria drug at ~$600k/year.
• MF: Deemed a blue ocean opportunity with essentially zero direct competition for anemia treatment in this patient population.
• PV: Competitive landscape includes Resveratide (Takeda) and other hepcidin inhibitors in late-stage trials; company differentiates via safety profile, ease of use (auto-injector), and monthly dosing to manage side effects quickly.
• Pricing Strategy: Plans to align with rare disease pricing models; potential for differentiated pricing across indications (e.g., lower price points for larger inflammation markets) or via single-dose/extended half-life antibodies.

Risks and Challenges:

• Regulatory Uncertainty: Specific Phase 3 endpoints and treatment durations for the MF study are still being defined in alignment with the FDA.
• Market Access: Concerns regarding Medicare/Medicaid Forever (MFN) potential impacts on international pricing, though the company believes rare disease launches can bridge this gap.
• Patient Identification: Need to effectively activate "disengaged" patient populations (approx. 8,000 patients) who currently avoid medical care due to lack of treatment options.
• Clinical Validation: Must prove the safety profile and efficacy of the monthly dosing schedule in PV compared to longer-interval competitors.

Management Commentary and Tone:

• Confidence: Management expressed high confidence and optimism, describing the Phase 3 EPP readout as "phenomenal" and the MF opportunity as "incredibly exciting" due to the lack of competition.
• Strategic Clarity: Clearly articulated a "lean" operational approach transitioning to a commercial model, emphasizing the ability to fund the entire roadmap without immediate need for external capital.
• Tone: Forward-looking, assertive regarding the therapeutic value proposition, and focused on patient quality of life improvements (e.g., eliminating phlebotomy, sunlight intolerance).

Analyst Questions and Answers:

• Q: Patient epidemiology and launch strategy?
  • A: Market segmented into 6,000 engaged patients (reachable via 24-person sales force) and 8,000 disengaged patients (targeted via call center and broader outreach).
• Q: MF study design and endpoints?
  • A: Goal to capture full market; transfusion-dependent patients will use transfusion reduction endpoints, while non-transfused patients will use hemoglobin increase (e.g., 1.5 g/dL) plus quality-of-life metrics.
• Q: Ex-US expansion?
  • A: Yes, Europe identified as primary market; plan to use a lean model and mitigate MFN risks.
• Q: Competitive positioning in PV?
  • A: Differentiation via safety (no anemia/injection site reactions), monthly dosing for reversibility, and auto-injector convenience, aiming to match the 70-80% phlebotomy-free rates of competitors.

Other Key Points:

• Mechanism of Action: Focus on modulating fundamental metabolites (heme and iron) in red blood cells, specifically targeting hepcidin to control iron availability.
• Data Presentation: Company plans to present Phase 2 data (approx. 60 patients) at the ASH conference, which will also serve as the data cut for the FDA End-of-Phase 2 meeting.
• Organizational Scale: Current workforce is 170 employees; plans to expand significantly to support commercial launch and multiple concurrent Phase 3 trials.
• Future Timeline: By this time next year, the company expects to be a commercial entity with the lead product on the market and two other programs in Phase 3.